- Inhibitors
- Antibodies
- Compound Libraries
- New Products
- Contact Us
Synonyms: CP-751871
Figitumumab (Anti-IGF1R / CD221) is a human monoclonal antibody directed against the insulin-like growth factor type I receptor (IGF1R) with potential antineoplastic activity. Figitumumab prevents IGF1 from binding to IGF1R with an IC50 of 1.8 nM. MW: 146.0 KD.
| Name | Citation | IGF-1R | Insulin Receptor | Others |
|---|---|---|---|---|
| Linsitinib (OSI-906) | 206 | IRR | ||
| NVP-AEW541 | 65 | FLT3,Tek,FLT1 | ||
| GSK1904529A | 26 | |||
| NVP-ADW742 | 24 | |||
| BMS-536924 | 26 | FAK,MEK,LCK | ||
| AG-1024 | 27 | |||
| GSK1838705A | 18 | ALK | ||
| BMS-754807 | 54 | TrkB,Met,TrkA | ||
| PQ 401 | 3 | |||
| Ginsenoside Rg5 | 0 | |||
| XL228 | 0 | ABL T315I,LYN,Aurora A | ||
| Picropodophyllin (AXL1717) | 48 | |||
| AZD3463 | 7 | ALK | ||
| S961 | 3 | |||
| Nordihydroguaiaretic acid (NDGA) | 1 | p300,HER2,lipoxygenase |
| Description |
Figitumumab (Anti-IGF1R / CD221) is a human monoclonal antibody directed against the insulin-like growth factor type I receptor (IGF1R) with potential antineoplastic activity. Figitumumab prevents IGF1 from binding to IGF1R with an IC50 of 1.8 nM. MW: 146.0 KD.
|
References |
|---|
| CAS No. | 943453-46-1 |
|---|---|
| Molecular Weight | 146 |
| Isotype | Human IgG1 |
| Source | CHO |
| Purification | AKTA |
| Sterility | 0.2 μM filtered |
| Formulation | 100 mM Pro-Ac, 20mM Arg, pH5.0 |
| Storage (From the date of receipt) |
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles. |
*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.